Randomized Trialvery high evidence
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
The New England journal of medicine·December 18, 2025·PMID 41406444
Why it mattersFor clinicians choosing incretin-based therapy in high-risk type 2 diabetes, this trial supports that tirzepatide does not appear to worsen cardiovascular outcomes compared with dulaglutide, a GLP-1 receptor agonist with established cardiovascular benefit. It helps frame tirzepatide as a cardiometabolically reasonable option when weight loss or glycemic potency is a priority.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled